News
Over a whirlwind three weeks, Sarepta Therapeutics has faced tough safety questions around its commercial gene therapy ...
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report second ...
Sarepta Therapeutics now trades at book value with strong cash and cost-cutting plans, while ELEVIDYS may regain broader use.
This regulatory relief, combined with several other compelling catalysts, creates a pathway for the stock to potentially ...
Zacks Investment Research on MSN1d
Sarepta Therapeutics (SRPT) to Report Q2 Results: Wall Street Expects Earnings Growth
Wall Street expects a year-over-year increase in earnings on higher revenues when Sarepta Therapeutics (SRPT) reports results ...
FDA permits use of Sarepta Therapeutics’ Duchenne therapy in younger patients after short-lived halt
The FDA said it was clearing the way for Sarepta Therapeutics to resume shipments of its gene therapy for Duchenne muscular ...
The FDA has placed multiple investigational gene therapy clinical trials on hold, signaling broader platform concerns.
Sarepta Therapeutics’ stock was soaring Tuesday after the FDA recommended lifting the pause on the company’s Duchenne ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback